Data as of Apr 17
| -0.05 / -1.30%|
The 6 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 8.00, with a high estimate of 9.00 and a low estimate of 4.00. The median estimate represents a +111.08% increase from the last price of 3.79.
The current consensus among 8 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.